“Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses triplet therapies for patients with melanoma and the sequencing challenges associated with the approvals of additional agents in the field.
“Though current immunotherapy regimens are showing significant activity in patients, Ribas says the response rate is not 100%; therefore, there needs to be investigations of other ways to modulate the immune system. Patients who benefit from PD-1 monotherapy should not receive any more, as it will lessen treatment-related toxicities, he adds.”
Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.